Results 281 to 290 of about 103,365 (348)

Rethinking control‐IQ+ technology: Simple strategies for easy optimization

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Control‐IQ+ is an automated insulin delivery (AID) algorithm approved for people with type 1 diabetes aged 2+ years and adults aged 18+ years with type 2 diabetes. While numerous publications support improved glycaemia and quality of life for people with diabetes, this practice paper is intended to encourage uptake for healthcare professionals
Viral N. Shah, Pratik Choudhary, Ilana Halperin, Ivana Rabbone, Dessi P. Zaharieva, Laurel Messer   +5 more
wiley   +1 more source

Impact of Glucagon-Like Peptide-1 Receptor Agonists on Hip Arthroplasty Outcomes: A Systematic Review and Meta-Analysis. [PDF]

Cureus
Zaffar H, Imran MA, Hussain S, Rushd F.
europepmc   +1 more source

SGLT2 inhibitors and mortality in older adults with diabetic kidney disease: A target trial emulation study

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Randomized controlled trials on sodium‐glucose cotransporter 2 (SGLT2) inhibitors have yielded inconsistent findings regarding mortality benefits. It remains unclear whether, and in which subgroups, SGLT2 inhibitors confer survival benefits in older adults with diabetic kidney disease (DKD).
Tatsuhiko Azegami, Hidehiro Kaneko, Akira Okada, Yuta Suzuki, Toshiyuki Ko, Kazuki Aoyama, Takashin Nakayama, Yuya Kimura, Katsuhiko Fujiu, Norifumi Takeda, Hiroyuki Morita, Takashi Yokoo, Koichi Node, Masaomi Nangaku, Norihiko Takeda, Hideo Yasunaga, Kaori Hayashi   +16 more
wiley   +1 more source

The Impact of Glucagon-like Peptide-1 Receptor Agonists on Cardiovascular-Kidney-Metabolic Health in Romanian Patients with Type 2 Diabetes: A Retrospective Study. [PDF]

J Clin Med
Lixandru N, Gaita L, Popescu S, Herascu A, Timar B, Timar R.   +5 more
europepmc   +1 more source

Comparative effectiveness of pharmacotherapy for heart failure with preserved ejection fraction: A systematic review and network meta‐analysis

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aim Heart failure with preserved ejection fraction (HFpEF) presents a therapeutic challenge, characterised by a paucity of validated treatments. Emerging data suggest that targeting adiposity is central to HFpEF pathogenesis. We conducted an updated network meta‐analysis to compare the efficacy of emerging and established HFpEF therapies ...
Szu‐Han Chen, Yu‐Wen Tseng, Chi‐Jung Huang, Shu‐Mei Yang, Marat Fudim, Shao‐Yuan Chuang, Shih‐Hsien Sung, Hao‐Min Cheng   +7 more
wiley   +1 more source

An oral glucose tolerance test in pregnancy and its association with future cardiovascular diseases

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims/hypothesis Gestational diabetes and abnormal 100‐g oral glucose tolerance test (OGTT) results in pregnancy are associated with type 2 diabetes, but their relationship with cardiovascular disease (CVD) is less clear. We evaluated the risk of CVD according to the number of abnormal OGTT values during pregnancy.
Tal Schiller, Linoy Gabay, Oren Barak, Alena Kirzhner, Haitham Abu Khadija, Gabriel Chodick, Edi Vaisbuch, Yael Barer   +7 more
wiley   +1 more source

Glucagon-Like Peptide-1 Receptor Agonist Use Does Not Impact Spine Surgery Outcomes: A Systematic Review and Meta-Analysis. [PDF]

Global Spine J
Ibrahim S, Durrani A, Ibrahim MT, Kuttner N, Glivar P, Singh VK, Yu E.   +6 more
europepmc   +1 more source

Estimating the excess expenditures associated with glucagon-like peptide-1 receptor agonist use among adults with diabetes in the United States. [PDF]

J Manag Care Spec Pharm
Akpan N, Zhou B, Rasu RS, Sambamoorthi U.   +3 more
europepmc   +1 more source

The Cardiovascular Physiology of Glucagon-like Peptide-1 Receptor Agonists: From Macro-level Outcomes to Micro-level Mechanisms

Masab Mansoor
openalex   +2 more sources

Prevalence of use and interest in using glucagon-like peptide-1 receptor agonists for weight loss: a population study in Great Britain. [PDF]

BMC Med
Jackson SE, Brown J, Llewellyn C, Mytton O, Shahab L.   +4 more
europepmc   +1 more source